In-silico study of Stevia Leaves (Stevia rebaudiana Bertoni) as Antidiabetic Drugs
Diabetes mellitus is a metabolic disorder due to abnormalities in insulin secretion, insulin action or both. Around 200 million people worldwide suffer from diabetes, most of which is type 2 diabetes. One of the targets of diabetes treatment is the DPP-4 enzyme which works to degrade incretin from the body. Sitagliptin, a DPP-4 inhibitor that has been approved for the treatment of type 2 diabetes. Besides using cytetic drugs, biochemical compound can also be used for diabetes therapy, one of which is stevia leaf. This research was conducted to select compounds contained in stevia leaves based on their interaction with DPP4 in silico. The purpose of this study is a potential compound from stevia leaves to be a candidate for antidiabetic drugs. Tests were carried out on DPP4 inhibitors, namely sitaglipin, and 10 compounds contained in stevia leaves. The results show that there are three potential compounds namely isosteviol, steviol and steviolmonoside. Testing the Lipinski's rule of five and pre-ADMET parameters shows that the three compounds have the potential to be used as candidates for antidiabetic drugs.
2. Liu Q, Chen L, Hu L, Guo Y, & Shen X. (2010). Small molecules from natural sources, targeting signaling pathways in diabetes. Biochimica et Biophysica Acta - Gene Regulatory Mechanisms,2019;1799(10–12):854–865. https://doi.org/10.1016/j.bbagrm.2010.06.004
3. National C. for B. I. (n.d.). Compound. In PubChem Database. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Stevioside
4. Kemkes RI. Hasil Utama Riskesdas 2018. Retrieved from http://www.kesmas.kemkes.go.id/assets/upload/dir_519d41d8cd98f00/files/Hasil-riskesdas-2018_1274.pdf, 2018
5. Kerru N, Singh-Pillay A, Awolade P, & Singh P. Current anti-diabetic agents and their molecular targets: A review. European Journal of Medicinal Chemistry, 152, 436–488. https://doi.org/10.1016/j.ejmech.2018.04.061, 2018
6. Gallwitz B. Clinical use of DPP-4 inhibitors. Frontiers in Endocrinology, 10(JUN), 1–10. https://doi.org/10.3389/fendo.2019.00389, 2019.
7. Aschner P, Kipnes M.S, Lunceford J.K, Sanchez M, Mickel C, & Williams-Herman, D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care, 29(12), 2632–2637. https://doi.org/10.2337/dc06-0703, 2006.
8. RSCB. 4A5S. https://doi.org/http://dx.doi.org/10.2210/pdb4A5S/pdb, 2012.
9. Chatsudthipong V, Muanprasat C. Stevioside and related compounds: Therapeutic benefits beyond sweetness. Pharmacology and Therapeutics, 121(1), 41–54. https://doi.org/10.1016/j.pharmthera.2008.09.007, 2019.
10. Bissantz C, Folkers G, & Rognan D. Protein-Based Virtual Screening of Chemical Databases . 1 . Evaluation of Different Docking / Scoring Combinations, 4759–4767. 2000.
11. Muchtaridi M, Yusuf M. Teori dan Praktek Penambatan Molekul (Molekular Docking). Bandung: Unpad Press. 2018.
12. Nursamsiar XI, Surantaatmadja S, & H. Tjahjono D. Absorption, Distribution and Toxicity Prediction of Curculigoside A and its Derivatives, 32–35. https://doi.org/10.2991/iccst-15.2015.7. 2015
13. Sharma P, Joshi T, Joshi T, Chandra S, & Tamta S. (2020). In silico screening of potential antidiabetic phytochemicals from Phyllanthus emblica against therapeutic targets of type 2 diabetes. Journal of Ethnopharmacology, 2020; 248: 112268. https://doi.org/10.1016/j.jep.2019.11226
14. Teotia P, Prakash D.S, & Dwivedi N. In silico Molecular Docking and ADME/Tox Study on Benzoxazole Derivatives Against Inosine 5’-Monophosphate Dehydrogenase. Asian Journal of Biotechnology, 2018;10(1):1–10. https://doi.org/10.3923/ajbkr.2018.1.10
15. Tan H.L, Chan K.G, Pusparajah P, Lee L.H, & Goh B.H. Gynura procumbens: An overview of the biological activities. Frontiers in Pharmacology, 7(MAR). https://doi.org/10.3389/fphar.2016.00052. 2016.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).